Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Balance Sheet: Assets
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04).
- Gross Profit Margin
- The gross profit margin exhibits a generally stable upward trend over the observed periods. Starting at 66.24% in early 2021, it gradually increases with minor fluctuations, reaching a peak of 69.2% in early 2024. Subsequently, the margin slightly decreases but remains above 67.9%, indicating consistent efficiency in production and cost management across the timeline.
- Operating Profit Margin
- The operating profit margin fluctuates moderately throughout the periods. It begins at 24.1% in early 2021, peaks at 25.61% mid-2023, and demonstrates some volatility around 24% to 25% in later periods. A minor decline occurs in late 2024, but the margin recovers to 25.44% by mid-2025, suggesting effective operational control with occasional variations likely due to changes in operating expenses or revenue mix.
- Net Profit Margin
- Net profit margin shows notable variability. Initial quarters in 2021 and early 2022 display rates around 18% to 22%, but a significant drop occurs in early 2023 to 13.77%. A remarkable spike is observed in late 2023 and early 2024, jumping above 39% and reaching 44.92%, potentially driven by extraordinary income or cost-saving measures. However, this peak is followed by a sharp decrease back to around 16% in late 2024, then gradually rises again up to 27.26% by mid-2025, indicating periods of both strong profitability and substantial fluctuation.
- Return on Equity (ROE)
- Return on equity trends follow a pattern similar to net profit margin with some delay. ROE rises steadily from 22.96% in early 2021 to a high exceeding 54% in early 2024, implying heightened returns to shareholders during this period. After the peak, ROE declines sharply in late 2024 but shows signs of recovery, ending at 31.69% by mid-2025. This pattern reflects fluctuations in profitability and efficiency in equity utilization over time.
- Return on Assets (ROA)
- Return on assets also exhibits variability, beginning at 8.76% in 2021, increasing steadily to a peak of over 22% in early 2024. Following this peak, ROA declines notably in late 2024 to approximately 8.24%, then experiences a moderate recovery to 13.03% by mid-2025. This indicates changes in the company's asset utilization efficiency, possibly influenced by asset base changes or earning power adjustments throughout the periods.
Return on Sales
Return on Investment
Gross Profit Margin
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||||
| Sales to customers | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04).
1 Q3 2025 Calculation
Gross profit margin = 100
× (Gross profitQ3 2025
+ Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024)
÷ (Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025
+ Sales to customersQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Gross Profit Trend
- The gross profit exhibits fluctuations over the reported quarters. Initially, there is an upward trajectory from approximately 15,258 million USD to a peak near 16,849 million USD by the end of 2021. Following this peak, a decline occurs during 2022, stabilizing around the 15,900 million USD mark. The gross profit dips more noticeably in early 2023, reaching a low near 14,207 million USD, before recovering gradually through 2023 and 2024, reaching values above 15,500 million USD. Toward the later periods in 2025, a moderate increase is observed again, culminating near 16,690 million USD.
- Sales to Customers Trend
- Sales to customers follow a somewhat parallel pattern with fluctuations in line with gross profit but with generally higher absolute values as expected. There is growth from roughly 22,321 million USD to nearly 24,804 million USD until the end of 2021. Afterwards, sales slightly decline in 2022 but remain relatively stable around the 23,700 million USD level. A more marked decrease is seen at the start of 2023, dropping to about 20,894 million USD. Subsequently, sales gradually increase over the following quarters, returning to approximately 22,500 million USD and reaching nearly 24,000 million USD toward the end of the reported periods in 2025.
- Gross Profit Margin Analysis
- The gross profit margin remains consistently robust throughout the timeline, starting around 66.24% and showing an overall increasing trend. By the end of 2021, the margin exceeds 68%, maintaining this favorable level through 2022 and 2023 with minor fluctuations. The margin further improves into 2024, peaking slightly above 69%, indicating enhanced efficiency or cost management relative to sales. Although slight decreases occur towards late 2024 and into 2025, the margin remains above 67%, signaling resilient profitability over time.
- Summary of Financial Patterns
- The data highlights cyclical variations in both gross profit and sales, with peaks typically at year-end periods and troughs occurring mainly in early quarters of subsequent years. Despite these fluctuations, the gross profit margin shows a steady upward trend, suggesting improved operational leverage or pricing strategies. The ability to sustain a margin near or above 68% indicates strength in cost control relative to sales revenue. The recovery in sales and gross profit following downturns implies resilience in business dynamics. Overall, the financial data demonstrate stable profitability amid variable sales volumes.
Operating Profit Margin
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Operating earnings | |||||||||||||||||||||||||
| Sales to customers | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04).
1 Q3 2025 Calculation
Operating profit margin = 100
× (Operating earningsQ3 2025
+ Operating earningsQ2 2025
+ Operating earningsQ1 2025
+ Operating earningsQ4 2024)
÷ (Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025
+ Sales to customersQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Operating Earnings
- Operating earnings show a generally fluctuating trend over the periods analyzed. After peaking at 6595 million US dollars in April 2021, a noticeable decline occurred through to December 2021 reaching 4892 million. A recovery phase followed in 2022, with earnings increasing and peaking again at 6216 million in October 2022 before declining towards the end of that year. Through 2023 and into early 2024, the earnings maintained a somewhat volatile profile, with a significant dip to 4193 million in December 2023, followed by an upward rebound in the subsequent quarters, ultimately reaching a high of 7033 million in September 2025. This pattern reflects variability in profitability that may be influenced by external market conditions or internal operational changes.
- Sales to Customers
- Sales to customers have exhibited a modestly variable trend with some contractions and expansions over time. Starting from 22321 million US dollars in April 2021, sales increased slightly to reach a peak around 24804 million in December 2021. Following this peak, a mild decrease was observed during 2022, dropping to approximately 23706 million at year-end. Through 2023 and into 2025, sales figures show relative stability with some fluctuations around the 21000 to 24000 million range, including a slight dip in mid-2024 and a subsequent recovery by late 2025. Overall, the data indicates a stable demand environment with periodic short-term variances.
- Operating Profit Margin
- The operating profit margin has remained relatively stable with slight oscillations around the mid-20% range. The margin started at 24.1% in April 2021 and peaked modestly above 25% several times, most notably reaching 25.61% in July 2023 and 25.44% in September 2025. Minor declines were noted in the end of 2024, reaching a value of 23.42%, suggesting periodic pressure on profitability. However, the operating margin consistently returned to levels close to or exceeding 24% thereafter, indicating persistent operational efficiency and cost management capacity despite the external and internal challenges evidenced by earnings and sales fluctuations.
Net Profit Margin
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings (loss) | |||||||||||||||||||||||||
| Sales to customers | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04).
1 Q3 2025 Calculation
Net profit margin = 100
× (Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025
+ Net earnings (loss)Q4 2024)
÷ (Sales to customersQ3 2025
+ Sales to customersQ2 2025
+ Sales to customersQ1 2025
+ Sales to customersQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analyzed financial data demonstrates fluctuating trends across net earnings, sales to customers, and net profit margin over the specified periods.
- Net Earnings (Loss)
- The net earnings exhibit notable volatility with periods of both growth and decline. From early 2021 to the end of 2022, earnings generally decreased from a high of $6,278 million in mid-2021 to a low of $3,520 million by the end of 2022. A marked decline into negative territory occurs in early 2023 with a significant loss of $68 million, followed by a sharp recovery and peak of $26,028 million in October 2023. Subsequent quarters show a return to positive earnings with values generally stabilizing between approximately $2,600 million and $11,000 million through mid-2025. This pattern indicates substantial earnings volatility, including an exceptional spike followed by normalization in the later periods.
- Sales to Customers
- Sales demonstrate relative stability compared to net earnings, with values generally ranging between $20,800 million and $24,000 million throughout the timeline. Sales peaked near $24,020 million mid-2022 but experienced a drop to the low $21,000 million range during 2023. A slight recovery in sales is observed from late 2023 onward, with figures climbing back to approximately $23,900 million by mid-2025. Overall, sales to customers show moderate fluctuations but maintain a narrow bandwidth without drastic declines or growth, reflecting steady demand conditions.
- Net Profit Margin
- The net profit margin showcases important variability aligned with net earnings’ fluctuations. Initial margins hovered around 18-22% through 2021 and 2022 but temporarily dropped to 13.77% in early 2023, coinciding with negative earnings. An extraordinary jump in margin occurs in late 2023, soaring above 39% and peaking at nearly 45% in early 2024, which corresponds with the exceptional net earnings surge in that timeframe. Post-peak, margins stabilize at a moderately high level around 15-27% through 2025, indicating improved profitability relative to sales compared to earlier periods.
In summary, the financial data reveals a pattern of relatively stable sales accompanied by significant volatility in net earnings and net profit margins. The pronounced earnings spike and corresponding margin increase around late 2023 suggest a non-recurring event or exceptional gain impacting financial performance. Following this, metrics tend to normalize but maintain levels indicative of sustained profitability improvements compared to earlier years. This overall trend highlights underlying resilience in revenue generation, tempered by fluctuations in profitability and earnings quality over time.
Return on Equity (ROE)
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings (loss) | |||||||||||||||||||||||||
| Total Johnson & Johnson shareholders’ equity | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04).
1 Q3 2025 Calculation
ROE = 100
× (Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025
+ Net earnings (loss)Q4 2024)
÷ Total Johnson & Johnson shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the financial data reveals notable fluctuations and trends in net earnings, shareholders' equity, and return on equity (ROE) over the observed periods.
- Net Earnings (Loss)
- Net earnings generally show variability across quarters with an overall trend that includes both growth and declines. Early periods reflect relatively stable earnings around 3,500 to 6,200 million USD, with a significant spike observed in October 2023 reaching above 26,000 million USD. However, this peak is preceded and followed by lower values, including a loss reported in April 2023. The fluctuations continue in subsequent quarters with earnings ranging between approximately 2,600 and 11,000 million USD toward the later periods.
- Total Shareholders’ Equity
- The shareholders’ equity demonstrates a slow and steady increase over time, starting from approximately 65,800 million USD in April 2021 and rising to roughly 79,300 million USD by September 2025. Some minor declines occur intermittently but are followed by recoveries, indicating overall growth in the company’s equity base.
- Return on Equity (ROE)
- ROE exhibits considerable volatility. In the initial quarters, ROE values fluctuate between approximately 22% and 28%, indicating stable profitability relative to equity. A sharp increase occurs in late 2023, with ROE reaching above 50%, likely tied to the extraordinary net earnings spike seen in the same period. Following this peak, ROE values revert to a more typical range between 20% and 32%, suggesting normalization after the exceptional event.
Overall, the financial data indicate that while shareholders’ equity grows steadily, net earnings and ROE experience substantial variability, including occasional extraordinary spikes. These spikes significantly influence profitability metrics for brief periods but are interspersed with more typical performance levels. This pattern suggests episodes of atypical earnings impacting return metrics alongside sustained equity base growth.
Return on Assets (ROA)
| Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings (loss) | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04).
1 Q3 2025 Calculation
ROA = 100
× (Net earnings (loss)Q3 2025
+ Net earnings (loss)Q2 2025
+ Net earnings (loss)Q1 2025
+ Net earnings (loss)Q4 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Earnings (Loss)
- The net earnings displayed substantial volatility over the observed periods. Initially, earnings remained positive and relatively stable from April 2021 through December 2022, with values generally ranging between approximately $3,500 million and $6,300 million. A notable exception occurred in April 2023, when earnings sharply fell to a negative value, indicating a loss. Following this dip, earnings rebounded strongly in subsequent quarters, peaking dramatically in October 2023 at over $26,000 million. After this peak, earnings adjusted downward but remained positive, fluctuating between roughly $2,600 million and $11,000 million through mid-2025. This pattern suggests episodic gains or significant one-time events impacting earnings during the period.
- Total Assets
- Total assets showed a generally upward trend over the timeframe but with some fluctuations. From April 2021 to December 2022, total assets increased moderately from about $172,500 million to nearly $187,400 million. However, in 2023, assets experienced a decline to around $166,000 million in October 2023, followed by a recovery and continued growth, reaching approximately $193,700 million by mid-2025. The temporary decrease in late 2023 may indicate asset disposals, revaluations, or other adjustments, after which asset levels stabilized at a higher plateau.
- Return on Assets (ROA)
- The ROA fluctuated between single and double digits, reflecting changes in profitability relative to asset base. Initially, ROA was strong, ranging from 8.76% up to over 11% through early 2022. It then showed movement between approximately 9.5% and 11% until early 2023. There was a sharp decrease to around 6.5% in April 2023, coinciding with the net earnings loss. Following this, ROA surged prominently above 20% during the later part of 2023 and early 2024, indicating significantly enhanced asset profitability, likely tied to extraordinary gains reflected in net earnings. Subsequently, ROA declined again to near 7-8%, then gradually improved to around 13% by the middle of 2025, suggesting recovery and more normalized profitability levels.
- Summary of Trends
- Overall, the data reveals episodic volatility in profitability and earnings, with a significant one-off event in late 2023 reflected by a large spike in net earnings and ROA. Total assets generally increased but showed a temporary dip coinciding with these earnings fluctuations. The financial performance trends suggest a cycle of stable earnings, a sudden loss, followed by a sharp recovery and then normalization. This pattern points to possible extraordinary items or restructuring activities impacting results during the period, requiring further investigation into the underlying causes.